Telix GM 2024
Telix's 2024 GM was held on Friday, 5th April 2024 at The Wesley Conference Centre in Sydney, Australia and...
Read moreLatest News
Category: Events
Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage theranostic programs at the 39th Annual European Association of Urology Congress (EAU24), Europe’s largest urological...
Read more
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
Telix today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative...
Read more
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 –...
Read more
Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers
Read more
New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:...
Read more
Telix Urology Innovation Showcase Webcast
Telix is pleased to provide a video recording of the Company’s briefing session for shareholders held on Wednesday, June 21, 2023, at The Yale Club in New York City....
Read more
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
Telix today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear...
Read more
Telix Urology Innovation Showcase – June 21, 2023, at The Yale Club, New York City
Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from...
Read more
Telix Opens European Radiopharmaceutical Production Facility
Telix today welcomes Willy Borsus, Vice-President of Wallonia, Minister of Economy, Research and Innovation, Digital, Agriculture, Urban Planning and Regional Planning to officially open Telix Manufacturing Solutions, the Company’s radiopharmaceutical production...
Read more